Published in Health Business Week, November 24th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Bayer.
Report 1: Bayer HealthCare, a member of the Bayer Group (BAY), announced findings from a study using Bayer Diagnostics' Serum HER-2/neu test that demonstrated metastatic breast cancer (MBC) patients whose serum HER-2/neu levels decreased by less than 20% experienced decreased benefit from trastuzumab-based therapy.
The data, from a pooled analysis of seven clinical trials in the United States and western Europe of MBC patients who received trastuzumab (with or without...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.